Elicio Therapeutics, Inc. Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature
Elicio Therapeutics, Inc. (ELTX) reported Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature of $300.00 thousand for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-13.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature · last filed 2025-05-13
- Elicio Therapeutics, Inc. adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2025-03-31 was $300.00K.
| Period end | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 3 month |
|---|---|
| 2025-03-31 | $300.00K 10-Q · filed 2025-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |